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Abstract The hereditary peripheral neuropathies are a
clinically and genetically heterogeneous group of diseases
of the peripheral nervous system. Foot deformities,
including the common pes cavus, but also hammer toes and
twisting of the ankle, are frequently present in patients with
hereditary peripheral neuropathy, and often represent one
of the ﬁrst signs of the disease. Pes cavus in hereditary
peripheral neuropathies is caused by imbalance between
the intrinsic muscles of the foot and the muscles of the leg.
Accurate clinical evaluation in patients with pes cavus is
necessary to exclude or conﬁrm the presence of peripheral
neuropathy. Hereditary peripheral neuropathies should be
suspected in those cases with bilateral foot deformities, in
the presence of family history for pes cavus and/or gait
impairment, and in the presence of neurological symptoms
or signs, such as distal muscle hypotrophy of limbs. Herein,
we review the hereditary peripheral neuropathies in which
pes cavus plays a key role as a ‘‘spy sign,’’ discussing the
clinical and molecular features of these disorders to high-
light the importance of pes cavus as a helpful clinical sign
in these rare diseases.
Keywords Pes cavus  Hereditary peripheral
neuropathy  Neurological evaluation 
Multidisciplinary management
Introduction
Pes cavus is a foot deformity characterized by a high arch
of the foot that does not ﬂatten with weight bearing; the
deformity can be located in the forefoot, midfoot, hindfoot,
or in a combination of all these sites (Figs. 1, 2). Pes cavus
is a common ﬁnding in the general population, with
prevalence of approximately 10% [1].
Frequently, pes cavus may be a sign of an underlying
neurological disorder, including spinal cord and
peripheral nerve pathologies, such us spino-cerebellar
ataxia and hereditary peripheral neuropathies. A previ-
ous retrospective analysis of patients undergoing pes
cavus surgery [2] revealed that almost one-third of
apparently idiopathic cases suffered from a neurological
disease.
Herein, we discuss the hereditary peripheral neuropa-
thies (HPN) in which pes cavus plays a key role as a ‘‘spy
sign.’’ A clear, complete, and detailed review of clinical
and molecular features of these rare disorders may be
useful in clinical management and differential diagnosis of
patients who present with pes cavus as almost single sign
of disease.
Hereditary peripheral neuropathies (HPN) are a hetero-
geneous group of peripheral nerve disorders, clinically
characterized by sensorial and/or motor impairment, with
reduction or absence of deep tendon reﬂexes [3].
Foot deformities, including pes cavus, hammer toes, and
twisting of the ankle, are commonly present in some HPN
forms, such as Charcot–Marie–Tooth (CMT) disease,
hereditary neuropathy with predisposition to pressure pal-
sies (HNPP), and distal hereditary motor neuropathy
(DHMN) [4], but are uncommon in the other HPN. We will
therefore discuss only the clinical features and genetic
basis of HPN associated with pes cavus.
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Charcot–Marie–Tooth disease
The most common form of HPN is hereditary motor and
sensory neuropathy (HMSN), also called Charcot–Marie–
Tooth (CMT) disease. Prevalence is estimated at about
17–40 per 100,000 [5].
CMT is a genetically heterogeneous disorder (Table 1),
classiﬁed into demyelinating (CMT1 and CMT4), axonal
(CMT2 and CMT4), and intermediate (CMT, CMTX,
CMT2E) forms, and caused by mutations in several genes
coding for structural myelin proteins, gap-junction pro-
teins, cytoskeleton components, enzymes, or transcription
factor. CMT is usually transmitted as an autosomal domi-
nant trait, although rarer X-linked (CMTX) or recessive
forms have been reported [6, 7]. CMT is a slow progressive
disease, usually with onset in the second or third decade.
Rarely, CMT arises in early infancy (Dejerine–Sottas and
congenital hypomyelination diseases) [8] with a severe
phenotype characterized by hypotonia and delay in motor
milestones. CMT onset may also occur later, generally with
a less aggressive clinical course [9].
The most common features in classical CMT phenotype
areskeletaldeformitiessuchaspescavuswith hammertoes;
less frequent skeletal signs are pes planus, twisting of ankle
and tripping, and painful foot callosities. Scoliosis could be
present in 10% of affected people [10, 11]. Neurological
examination shows characteristic signs of a sensorimotor
peripheral neuropathy. Sensory signs are usually less
prominent (70%) than motor ones [12]. The most frequent
ﬁndings [13] are ataxia, hypoesthesia, and loss of vibration,
two-point discrimination, and joint position sense. Motor
impairment,whichusuallybecameevidentduringthecourse
of disease,isresponsible forupper and lower limb weakness
and atrophy, with main en griffe (Fig. 1) and ‘‘inverted
champagne bottle’’ legs. Steppage gait and foot drop are the
ﬁrst most common motor signs. Deep tendon reﬂexes are
diminished or absent [14]. Muscle cramps, cold feet, acro-
cyanosis, and postural tremor are frequent complaints.
Electroneurography allows classiﬁcation of CMT dis-
ease into two main forms: CMT1 or demyelinating form,
characterized by a marked slowing in nerve conduction
velocities (by deﬁnition, \38 m/s in upper limb motor
nerves) and by a primary myelinopathy; and CMT2 or
axonal form, in which nerve conduction values are pre-
served or only mildly slowed ([38 m/s in upper limb
motor nerves) and the axon is the primary disease target
[15]. The existence of a CMT subgroup showing nerve
conduction velocity (NCV) values ‘‘intermediate’’ between
CMT1 and CMT2 has been also reported [16, 17].
As previously reported, CMT diagnosis is based on
clinical examination, electrophysiological ﬁndings, and
molecular testing. In selective cases, such as in patients with
sporadic form or in whom molecular investigations result
unable to demonstrate DNA defects, nerve biopsy might
give relevant information for diagnosis and differential
diagnosis. In particular, the typical histological marker
of demyelinating neuropathies is represented by the pres-
ence of basal lamina ‘‘onion bulbs,’’ determined by con-
centric proliferation of Shawn cell cytoplasmic processes
during the demyelination phenomenon and the remyelina-
tion tentative. In the advanced phase, loss of normal
myelin covering (‘‘nude axon’’) has also been reported.
Fig. 2 Pes cavus in a patient with CMT1A
Fig. 1 Pes cavus and main en griffe in a patient with CMT1A
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monostratiﬁed ‘‘simple onion bulbs’’ have been described
in CMT2 [3].
There are no pharmacologic cures for CMT. A well-
balanced diet and weight control can help minimize
disability. Dietary supplements such as creatine, and
Table 1 Genetic classiﬁcation
of hereditary motor and sensory
neuropathies





CMT1A: PMP-22 Dominant/sporadic 17p11
CMT1B: P0 protein Dominant lq22
CMT1C: LITAF Dominant 16pl3
CMT1D: EGR2 Dominant 10q21
CMT1E: P0 protein Dominant lq22
CMT1F: Neuroﬁlament light chain Dominant/sporadic 8p21
HMSN2-CMT2
CMT2A1: KIF1B Dominant lp36
CMT2A2: MFN2 Dominant lp36
CMT2B: RAB7 Dominant 3ql3-q22
CMT2C: TRPV4 Dominant 12q23-q24
CMT2D: GARS Dominant 7pl5
CMT2E: Neuroﬁlament light chain Dominant 8p21
CMT2F: HSPB1 Dominant/recessive 7q11-q21
CMT2G: Dominant 12ql2
CMT2I: PO Dominant lq22
CMT2J: PO Dominant lq22
CMT2L: HSPBE Dominant 12q24
AR-CMT2A Lam in A/C Recessive lq21.2
AR-CMT2E Med25 Recessive 19ql3.3
CMT2K: GDAP1 Dominant/recessive 8q21
HMSN3—DSN/CHN
DSNA PMP-22 Dominant/recessive 17p11-2
DSNB MP2 Dominant/recessive lq22
DSNC EGRP2 Dominant 10q21/EGR2
DSND Dominant Sq23-24
DSN PRX Recessive 19ql3.1-13.2
DSN GDAP1 Recessive 8ql3-21.1
Congenital hypomyelination
CHA PMO-22 Dominant 17p11.2
CHB MP2 Dominant lq22
CHC EGRP2 Dominant/recessive 10q21
HMSN4-CMT4
CMT4A: GDAP1 Recessive 8q21
CMT4B1: MTMR2 Recessive 11q23
CMT4B2: SBF2 Recessive 11p15
CMT4C: SH3TC2 (KLAA1985) Recessive 5q32
CMT4D: NDRG1 Recessive 8q24
CMT4E: EGR2 Dominant/recessive 10q21
CMT4F: Periaxin Recessive 19ql3
CMT4H: FGD4 Recessive 12ql2
CMT4J FIG4 Recessive 6q21
HSMN5
Silver syndrome Seipin/BSCL2 Dominant 11ql3
Troyer syndrome SPG20 Recessive 13ql2.3
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123co-enzyme Q have not been proven effective in treating
CMT. Aerobic exercise and rehabilitation play an essential
role in preserving quality of life of patients with CMT. A
small percentage of patients with inherited neuropathy may
respond to immunomodulatory therapy, such as prednisone
or intravenous gammaglobulin (IVIG). Potentially neuro-
toxic medications, such as vincristine or cisplatinum, should
be avoided [18]. Experimental studies showed that proges-
terone antagonist improves neuropathy in CMT1A rats, and
it represents a promising pharmacologic target for CMT1A
patients [19, 20].
Dejerine–Sottas neuropathy and congenital
hypomyelinating neuropathy
Dejerine–Sottas (DSN) and congenital hypomyelinating
(CHN) neuropathies are rare, severe, infantile-onset,
demyelinating peripheral nerve diseases.
DSN is transmitted as an autosomal dominant or
recessive trait (Table 1). Clinical onset occurs at up to
2 years of age, with motor and sensory impairment and
skeletal deformities, more frequently represented by sco-
liosis. NCV of DSN patients is greatly compromised, with
values \15 m/s. Sural nerve biopsies could show marked
demyelination or predominant axonal loss [8, 18].
CHN, an autosomal dominant or recessive disease
(Table 1), is characterized by severe hypotonia (‘‘ﬂoppy
infant’’), dysphagia, and respiratory insufﬁciency, usually
occurring within the ﬁrst year of life. NCV is very slow
(\10 m/s), and sural nerve biopsy presents pathological
features similar to those of DSN [16, 17].
Hereditary neuropathy with liability to pressure palsies
The prevalence of hereditary neuropathy with liability to
pressure palsies (HNPP) is estimated to be at least 16 per
100,000 [21].
HNPP is an autosomal dominant disorder due to a
deletion in chromosome 17p11.2 which codes for periph-
eral myelin protein (PMP22), an integral membrane protein
that is a major component of myelin in the peripheral
nervous system [22].
Patients present acute and transient episodes of focal
neuropathies, commonly affecting the ulnar, radial, and
peroneal nerves and the brachial plexus. These episodes are
typically painless, recurrent, and occur after trauma or
pressure, or with no evident precipitating factor [23]. The
palsies may be debilitating, last for days to weeks, and
require installation of speciﬁc orthosis. Onset of HNPP is
usually in adolescence, with a high degree of penetrance;
however, clinically asymptomatic gene carriers are repor-
ted. Neurological examination could evidence hypoactive
deep tendon reﬂexes and mild pes cavus, even in clinically
asymptomatic patients [24].
With ageing, these patients can have a signiﬁcant clin-
ical overlap with CMT1, as the repeated injuries to the
nerve can prevent full reversal.
Electrophysiological examination shows prolonged
motor and sensory nerve conduction velocities (NCV) [25]
and conduction blocks that are characteristic of the affected
nerves, especially over entrapment sites. NCV abnormali-
ties are also present in those nerves apparently unaffected
by palsy and in asymptomatic gene carriers [26].
Histological analysis of sural nerve biopsies shows
segmental area of de- and remyelination. The pathological
hallmark of HNPP is presence of tomacula, consisting of
massive variable myelin overfolding [27]. In rare of HNPP
patients nerve biopsy could be present only the axonal
regeneration signs [28].
There is no speciﬁc treatment for HNPP. Current man-
agement consists of early detection and diagnosis of the
disease, to reduce excessive force or repetitive movements,
or to avoid static joint positions. Chemotherapeutic agents,
such as vincristine, should be used with great caution [29].
Distal hereditary motor neuropathies
Distal hereditary motor neuropathies (dHMNs) are very
rare genetic disorders (approximately prevalence rate of
1/100,000) [30], inherited as an autosomal dominant,
autosomal recessive or X-linked trait [31–33] (Table 2).
dHMN usually presents as a classical peroneal muscular
atrophy syndrome without sensory symptoms [34]. The
clinical picture consists of progressive weakness and
wasting of the extensor muscles of the toes and feet. Later,
Table 2 Genetic classiﬁcation of distal hereditary motor
neuropathies
Type Inheritance Gene/locus
HMN I AD Unknown
HMN II AD HSP27 (HSPB1)
HMN II AD HSP22 (HSPB8)
HMN III AR 11q13
HMN IV AR 11q13
HMN V AD GARS
HMN V AD BSC12
HMN VI AR IGHMBP2
HMN VIIA AD 2q14
HMN VIIB AD DCTN1
HMN/ALS4 AD SETX
HMN-J AR 9p21.1-p12
Congenital distal SMA AD 12q23-12q24
Distal hereditary motor neuropathies (http://www.ncbi.nlm.nih.gov/
omim)
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123weakness and wasting also involve the distal upper limb
muscles. Foot deformity is a common feature. Additional
features are represented by involvement of hands, vocal
cord paralysis, diaphragm paralysis, and pyramidal tract
signs [35].
In dHMN patients, electromyography evidences signs of
chronic denervation, and motor NCV study shows an
amplitude reduction of compound muscle action potentials
or a moderate decrease in velocity. Sensory nerve con-
ductions and amplitudes were normal [4, 36].
Sural nerve biopsy has rarely been performed in dHMN
patients and usually showed normal ﬁndings [4]. Muscle
biopsy shows neurogenic damage related to lower motor
neuron degeneration [37].
dHMN has no speciﬁc treatment. Patients need neuro-
logical follow-up to evaluate the disease’s clinical pro-
gression and for referral to rehabilitation or orthopedic
service for correct management of complications.
Etiopathogenesis of pes cavus in HPN
Pes cavus in HPN derives from plantar ﬂexion deformity of
the ﬁrst metatarsal due to imbalance between the intrinsic
muscles of the foot and the muscles of the leg. The exact
physiopathological mechanisms responsible for pes cavus
genesis in HPN is not entirely clariﬁed, even if two main
hypotheses have been formulated [38].
The ﬁrst hypothesis assigns an important role in the
pathogenesis of this skeletal deformity to overaction of the
peronei in comparison with the antagonist tibialis anterior,
secondary to the leg muscle’s amyotrophy pattern in the
disease. In particular, it has been supposed that a weak per-
oneus brevis is overpowered by a relatively stronger tibialis
posterior, causing adduction of the forefoot and inversion of
the hindfoot. In addition, a weak tibialis anterior is
overpoweredbyastrongerperoneuslongus,causingplantar-
ﬂexion of the ﬁrst metatarsal and anterior pes cavus [12, 39–
41]. The intrinsic foot muscles develop contractures, while
the long extensor to the toe muscles, recruited to assist in
ankle dorsiﬂexion, causes claw toes deformity.
The second hypothesis is that precocious and primary
involvement of intrinsic foot muscles is responsible for
the pathogenesis of pes cavus, because the deformity is
observed in the early stages of the disease, also when there
is not yet evidence of leg muscle weakness [42]. A mag-
netic resonance imaging (MRI) study of amyotrophic leg
and foot muscles performed in patients with CMT [43]
reported precocious fatty inﬁltration of intrinsic foot mus-
cles, also when leg muscles are still preserved. The authors
deduced that the weakness of the lumbricals and the other
intrinsic foot muscles, due to selective denervation, could
cause the dorsiﬂexion of metatarsophalangeal joints,
initially responsible for the ﬂattening of the transverse
arcus plantaris and the clawing of the toes. Dorsiﬂexion of
metatarsophalangeal joints during gait could also deter-
mine the wrapping around the metatarsal head of the
plantar aponeurosis and the contraction of the short ﬂexors,
with secondary shortening of the Achilles tendon and
limitation of ankle dorsiﬂexion. A subsequent MRI muscle
study in CMT patients also seems to conﬁrm a possible
primary role of intrinsic foot muscle in pes cavus patho-
genesis [44]. The sensitivity of MRI for detecting preco-
cious denervation changes in early stages of HMN and
CMT has been also recently conﬁrmed [45].
In conclusion, the foot deformity pes cavus, secondary
to plantar ﬂexion deformity of the ﬁrst metatarsal, could be
associated to several neurological disorders, including
spinal cord and peripheral nerve pathologies, such us spi-
no-cerebellar ataxia and hereditary peripheral neuropathies.
In this article, we have reported the HPN in which pes
cavus plays a key role as a ‘‘spy sign’’ [46, 47], as a pre-
cocious manifestation of HPN. Accurate clinical evaluation
in patients with pes cavus is therefore necessary to exclude
or conﬁrm the presence of contemporary involvement of
peripheral nerves [48, 49], especially in the early stage of
Fig. 3 When pes cavus might reveal HPN: a proposed diagnostic
algorithm. NCS nerve conduction studies, HPN hereditary peripheral
neuropathies
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123the disease, when other signs of HPN may not yet be
present or evident.
When should HPN be suspected in a patient with pes
cavus? Clinical data suggestive of HPN are represented by
evidence of: bilateral pes cavus, positive family history for
pes cavus and/or gait impairment, distal muscle hypotrophy
of limbs, and sensorial and/or motor dysfunction.
When one or more of these signs are present, the patient
should be subjected to neurological evaluation to complete
the HPN diagnostic algorithm, based on electroneurograph-
ysiological studies and, subsequently, molecular analysis
(see Fig. 3).
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